1WHO. Ebola data and Statistics. Situation summary. May 11,2016, <http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary–20160511?lang = en> (
2Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371, 1418–1425, doi:10.1056/NEJMoa1404505 (2014).
3Etard, J.-F. et al. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. The Lancet Infectious Diseases 17, 545–552, doi:10.1016/s1473–3099(16)30516–3 (2017).
4Group, P. I. S. et al. A Longitudinal Study of Ebola Sequelae in Liberia. N Engl J Med 380, 924–934, doi:10.1056/NEJMoa1805435 (2019).
5Msellati, P. et al. [Revival after Ebola: multidisciplinary assessment at 1 year, prospect and follow-up study of surviving patients from Ebola in Guinea (PostEboGui cohort)]. Bull Soc Pathol Exot 109, 236–243, doi:10.1007/s13149–016–0526-x (2016).
6Bwaka, M. A. et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179 Suppl 1, S1–7, doi:10.1086/514308 (1999).
7Kibadi, K. et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 179 Suppl 1, S13–14, doi:10.1086/514288 (1999).
8Rodriguez, L. L. et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179 Suppl 1, S170–176, doi:10.1086/514291 (1999).
9Rowe, A. K. et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 Suppl 1, S28–35, doi:10.1086/514318 (1999).
10Mattia, J. G. et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. The Lancet Infectious Diseases 16, 331–338, doi:10.1016/s1473–3099(15)00489–2 (2016).
11McElroy, A. K. et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 112, 4719–4724, doi:10.1073/pnas.1502619112 (2015).
12Ruibal, P. et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100–104, doi:10.1038/nature17949 (2016).
13Dahlke, C. et al. Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection. J Infect Dis 215, 287–292, doi:10.1093/infdis/jiw508 (2017).
14Kash, J. C. et al. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Sci Transl Med 9, doi:10.1126/scitranslmed.aai9321 (2017).
15Kerber, R. et al. Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. J Infect Dis 218, S496-S503, doi:10.1093/infdis/jiy429 (2018).
16Colavita, F. et al. Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014(-)2016 Outbreak in West Africa. Viruses 11, doi:10.3390/v11040373 (2019).
17Reynard, S. et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight 4, doi:10.1172/jci.insight.125106 (2019).
18Sow, M. S. et al. New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. J Infect Dis 214, 1475–1476, doi:10.1093/infdis/jiw078 (2016).
19Ayouba, A. et al. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. J Clin Microbiol 55, 165–176, doi:10.1128/JCM.01979–16 (2017).
20Keita, A. K. et al. Serological Evidence of Ebola Virus Infection in Rural Guinea before the 2014 West African Epidemic Outbreak. Am J Trop Med Hyg 99, 425–427, doi:10.4269/ajtmh.18–0105 (2018).
21See, P. et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science 356, doi:10.1126/science.aag3009 (2017).
22Chujo, D. et al. ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults. PLoS One 8, e55595, doi:10.1371/journal.pone.0055595 (2013).
23Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167–174, doi:10.1002/cyto.a.21015 (2011).
24Caradonna, L. et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des 8, 995–1005 (2002).
25Brenchley, J. M. & Douek, D.C. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 3, 356–361, doi:10.1097/COH.0b013e3282f9ae9c (2008).
26Olsen, P. S. Role of Epidermal Growth-Factor in Gastroduodenal Mucosal Protection. Journal of Clinical Gastroenterology 10, S146-S151, doi:Doi 10.1097/00004836–198812001–00022 (1988).
27Gonzalez, V. D. et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 183, 6612–6618, doi:10.4049/jimmunol.0901437 (2009).
28Milush, J. M. et al. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV–1 infection. Retrovirology 10, 158, doi:10.1186/1742–4690–10–158 (2013).
29Cimini, E. et al. Different features of Vdelta2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl Trop Dis 11, e0005645, doi:10.1371/journal.pntd.0005645 (2017).
30Liu, X. et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol 18, 4, doi:10.1186/s13059–016–1137–3 (2017).
31Schieffelin, J. S. et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371, 2092–2100, doi:10.1056/NEJMoa1411680 (2014).
32Hunt, L. et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15, 1292–1299, doi:10.1016/S1473–3099(15)00144–9 (2015).
33Monticelli, L. A. et al. IL–33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci U S A 112, 10762–10767, doi:10.1073/pnas.1509070112 (2015).
34Williamson, L. E. et al. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. J Virol 93, doi:10.1128/JVI.01439–18 (2019).
35Rimoin, A. W. et al. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J Infect Dis 217, 223–231, doi:10.1093/infdis/jix584 (2018).
36Sobarzo, A. et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 208, 299–309, doi:10.1093/infdis/jit162 (2013).
37Davis, C. W. et al. Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell 177, 1566–1582 e1517, doi:10.1016/j.cell.2019.04.036 (2019).
38Varkey, J. B. et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med 372, 2423–2427, doi:10.1056/NEJMoa1500306 (2015).
39Diallo, B. et al. Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. Clin Infect Dis 63, 1353–1356, doi:10.1093/cid/ciw601 (2016).
40Deen, G. F. et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report. N Engl J Med 377, 1428–1437, doi:10.1056/NEJMoa1511410 (2017).